fool.comAUG 231 min read$CAH

Cardinal Health's Medical Segment Boss Sold $8 Million in Stock. Here's What to Know

Stephen M. Mason, CEO of Cardinal Health's GMPD Segment, sold 35,000 shares (55% of his position) for $8.27 million on August 18, leaving 18,061 shares worth $4.24 million. Cardinal Health (CAH) has a $55.0B market cap, $254.2B TTM revenue, and $1.7B TTM net income. The stock was up 57% over the past year.

Original reporting

fool.com

Published Aug 23, 2026, 2:45 PM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Aug 23, 2026, 3:19 PM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

Cardinal Health's Medical Segment Boss Sold $8 Million in Stock. Here's What to Know — source image — Source · fool.com

Decision brief

The 30-second read

$CAHBearishLow

Why it matters

The disclosure provides fresh data on insider sentiment for Cardinal Health.

Market read

New insider sale may influence short-term trading decisions on CAH.

What to watch

The sale price was near recent market levels, suggesting no panic selling.

Relevance 6/10Novelty 7/10Timing: post‑market August 18

Background

Form 4 filing disclosed the insider's sale and remaining holdings.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$CAHBearishMedium confidence

Context

CEO of Cardinal Health's medical segment sold 35,000 shares for $8.3M, reducing his stake to 18,061 shares.

Expected impact

Potential modest downside pressure over the next few days.

Evidence & confidence

Sale represents a large portion of insider's holdings and is disclosed via a Form 4, indicating possible concerns.

Market effects

Sector

May raise questions about confidence in Cardinal Health's medical segment among healthcare investors.

Regional

Limited to US healthcare sector.

Global

Minimal global impact.

Counterpoint

What could challenge this read

Insider sell could be routine diversification, not a negative signal.

Key entities

person
Stephen M. Mason
CEO of Cardinal Health's GMPD Segment.
company
Cardinal Health, Inc.
Global healthcare services and products provider.

Read at source ← All news

SEP 7

$CAHMedAI 8/10

4 companies on verge of settling US opioid lawsuits

AmerisourceBergen, Cardinal Health, McKesson, and Johnson & Johnson are nearing a $26B settlement for opioid lawsuits. New York reached a separate $1B deal with the distributors. Johnson & Johnson will contribute up to $5B nationally. Trials continue elsewhere.

pressdemocrat.com3 min

SEP 3

$CAHHighAI 8/10

Jim Cramer Notes Cardinal Health (CAH) is “Too Attractive to Ignore”

Jim Cramer highlighted Cardinal Health (CAH) as a favorite, citing its specialty pharmaceuticals and healthcare services growth. Q4 revenue rose 6% to $63.7B but missed estimates, while adjusted EPS was $2.91. Fiscal 2027 guidance includes non-GAAP EPS of $12.40-$12.60 and adjusted free cash flow of $3.5B-$4B. Risks include execution, drug pricing, and customer concentration.

insidermonkey.com3 min

AUG 19

$CAHHighAI 8/10

Cardinal Health’s (CAH) Big Earnings Beat Hides a More Complicated Story

Cardinal Health (CAH) reported Q4 2026 earnings with non-GAAP EPS up 40% YoY to $2.91, including a $0.31 one-time tariff refund. Revenue reached $63.7B, up 6% YoY. Full-year adjusted free cash flow hit $5B. Guidance suggests slower growth ahead. The company expanded its buyback program by $5B to $6.4B.

yahoo.com2 min

AUG 18

$CAHHighAI 9/10

Cardinal Health (CAH) Q4 2026 Earnings Call Transcript

Cardinal Health (CAH) reported Q4 2026 revenue of $63.7B, up 6%, driven by Pharmaceutical and Specialty Solutions. Non-GAAP EPS was $2.91, up 40%. Fiscal 2027 guidance includes 3-5% pharma revenue growth and 8-11% profit growth. The company plans $1B in share repurchases and increased its authorization to $6.4B. Management cited risks from geopolitical instability and IRA price changes.

fool.com6 min

AUG 18

$CAHMed

5 Revealing Analyst Questions From Cardinal Health’s Q2 Earnings Call

Cardinal Health reported Q2 revenue of $63.67B, below Wall Street’s $65.42B estimate, but adjusted EPS of $2.60 beat the $2.42 estimate. Management cited demand in Pharmaceutical and Specialty Solutions and progress on its improvement plan in Global Medical Products and Distribution. Guidance for FY2027 adjusted EPS midpoint was $12.50. Analysts asked about specialty growth, M&A, regulatory impacts, and input costs.

financialcontent.com7 min

AUG 17

$BAXMed

Baxter’s interim CFO is leaving for Cardinal Health

Baxter said in SEC filings that interim CFO Anita Zielinski will leave in September. She will join Cardinal Health as chief accounting officer and SVP of finance on Nov. 5, with a $750,000 sign-on bonus and $1 million in time-vesting RSUs. Baxter has not named a successor. Baxter recently raised its full-year outlook to 3%-4% sales growth and adjusted EPS of $1.95-$2.15.

massdevice.com4 min